DRKS00010937
Completed
Not Applicable
A Fecal marker of Intestinal inflammation for RElapse prediction in routine monitoring of Crohn's disease patients (FIRE) - FIRE
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- K50.1
- Sponsor
- AbbVie Deutschland GmbH & Co. KG
- Enrollment
- 525
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Participating Crohn's disease patients are required to meet all of the following criteria:
- •with status post moderate / severe disease flare which required treatment with steroids, immunosuppressives (Thiopurine,Methotrexat), and / or anti\-TNF; currently in clinical remission (HBI \< 5\) for at least 1 month under therapy with immunosuppressives and / or TNF antibodies; ileocecal and / or colonic disease, with or without involvement of proximal (small bowel, gastroduodenal) GI areas.
Exclusion Criteria
- •active disease (HBI \= 5\); current treatment of CD with corticosteroids; disease patterns restricted to proximal (small bowel, gastroduodenal) GI areas; pregnancy.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Detection of FIT- , fecal- and mucosa associated microbiome and microRNA in patients with suspected colorectal adenomas or cancerMicrobiome, MicroRNA, Colorectal cancer, AdenomasNL-OMON27020Erasmus Medical Center160
Completed
Not Applicable
Research for biomarkers of inflammatory bowel disease. - Investigation of the usefulness of LRG for evaluation of disease condition after adalimumab treatmentsJPRN-UMIN000019958Iwate Medical University Kochi Medical School Hospital Keio University School of Medicine80
Completed
Not Applicable
Identification of new biomarkers for intestinal barrier functioHealthy adultsJPRN-UMIN000039148Meiji Co., Ltd.112
Completed
Not Applicable
Analysis of intestinal flora by T-RFLPHealthyJPRN-UMIN000004123St. Luke's International Hospital100
Completed
Not Applicable
Detection of FIT- , fecal- and mucosa- associated microbiome and microRNA in patients with suspected colorectal adenomas or cancerNL-OMON48887Erasmus MC, Universitair Medisch Centrum Rotterdam160